Poster Board Number	First Name	Last Name	Organisation	Title
1	Louise	Affleck	Revvity	The power of combining PROTAC degraders targeting cyclin-dependent kinases (CDK4/CDK6) with AlphaLISA® SureFire® screening technology for the study of cell cycle regulation in oncology
2	Masih	Alam	Immundnz	An adaptable in vitro cytokine release assay (CRA): susceptibility to cytokine storm in COVID-19 as a model
3	Tayo	Alleyne-weir	Domainex	Leveraging Bivalent Molecules and Biophysical / Biochemical Techniques for Enhanced Therapeutic Potential
4	Imogen	Andrews	Institute Of Cancer Research	A Structure-Based Approach to Developing Novel Splicing Modulators
5	Nicholas	Barnes	Celentyx Ltd	A human monocyte-derived microglial model for modelling neuroinflammation associated with neurological and psychiatric conditions; identification of distinct modulators for distinct microglial functions
6	Sylvia	Boj	HUB Organoids B.V.	Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity
7	Paola	Bonetti	Axxam S.p.A.	Harnessing antisense oligonucleotide technologies to target RNA: Antisense oligonucleotide screening for splicing modulation and target degradation.
8	Erwin	Brenndörfer	Pelago Bioscience	Unbiased selectivity profiling - Cellular Thermal Shift Assay (CETSA) with MS detection
9	Steven	Broadbent	Axol Bioscience	A Blinded Compound Study on a Human Cortical Tri-Culture Model using Isogenic iPSC-derived Cortical Excitatory Neurons, Cortical Inhibitory Interneurons and Astrocytes.
10	Andrew	Brown	Ikherma Consulting Ltd	The state-of-the-art in secondary pharmacology and its impact on the safety of new medicines
11	Jarle	Bruun	Oncosyne As	µCAN – drug discovery, development and diagnostics using clinical grade drug screening and predictive phenotyping of patient-derived tumoroids
12	Adam	Buckle	Arrayjet Ltd	Small Molecule Microarray (SMM) as a tool for rapid, efficient hit-identification against both protein and RNA targets
13	Russell	Buckley-Taylor	Spt Labtech	Accelerating Drug Discovery at Totus Medicines: DNA-Encoded Library Screening with firefly®
14	Carly	Bunston	Molecular Devices UK Ltd.	Patient-Derived 3D ReadyTM Organoids for High Throughput Screening
15	Zoe	Caple	Sygnature Discovery	Unwinding the complexities of helicases as compelling drug targets in oncology
16	Oliver	Carney	BMG LABTECH	Competition assay using Fluorescence Polarization to determine the Residence Times for Calcitonin and AMYR agonist, AM833
17	Anna	Ceesay	MRC Mitochondrial Biology Unit,	Mass Spectrometry-Based Methods for Target Validation for Covalent Hit Finding
18	Fabienne	Charrier-Savournin	Revvity	Revolutionizing Autophagy with HTRF LC3B-II Assay, a No-Wash Immunossay for Specific and Reliable LC3B-II Detection, Paving the Way Beyond Western Blot

19	Ravindra	Chaudhari	Nanotemper Technologies	Measure affinities of membrane proteins in any environment with Monolith X
20	Kyle	Chen	CCIR	Applications of NMR Screening Techniques to Fragment-Based Drug Discovery
21	Joanne	Clark	University Of Birmingham	Multivalent Nanobodies : Novel Agonists for Platelet Activation
22	Duncan	Clark	Z7 Biotech Ltd	Detail Pharmacology: de-risking drug targets and hit/lead compounds
23	Rachel	Cooley	The Institute Of Cancer Research	Discovery of a chemical tool that modulates alternative splicing in non-small cell lung cancer (NSCLC)
24	Maxime	Couturier	AstraZeneca	A high throughput compatible workflow for the biochemical characterisation of molecular glues
25	James	Craswell	Domainex	The Application of Spectral Shift to Drug Discovery Projects
26	Richard	Cuthbert	Bio-Rad Laboratories	Improving Flow Cytometry Data with StarBright Dyes; Fluorophores with High Stability and Assay Compatibility
27	Nicholas	Dong	Gcatbio	Advancing Drug Discovery: Using mMPS High-Throughput Synthesis Technology to Elevate Variant Library Precision
28	Zoe	Donnellan	Immunocore	Recent improvements in ImmTAX molecule screening: Implementing automation and developing new assays
29	Vincent	DUPRIEZ	Revvity	Unveiling KRAS Inhibitors and Degraders in Cancer Research with HTRF KRAS Cell-Based Immunoassay
30	Jonathan	Faherty	Spt Labtech	Transforming PCR protocols in pandemic response with automated non-contact liquid dispensing
31	Marina	Fedorova	Gsk	Customisable protein expression
32	Daniel	Garcia West	Merck	Development of an Enhanced Sensitivity Immunogenicity (ADA) Assay on the Next Generation SMC™ Technology
33	Grainne	Gernon	Astrazeneca	Integrated CRISPR screening pipeline and target prioritisation framework to identify synthetic lethal interactions
34	Alison	Gordon	Charnwood Discovery	Phenotypic Assays – Diving into the Cellular Response to Expand the Druggable Target Space
35	Enrico	Grassilli	Insimili	An in vitro tumor model for High-Throughput Screening of innovative Triple-Neg Breast Cancer Drugs
36	Alessandro	Gregori	Core Life Analytics	High content image analysis of human cortical adherent organoids: 3D MICro-brains
37	Ryan	Guilbert	Astrazeneca	Development and implementation of a target-agnostic biochemical HiBiT artifact assay to identify artefactual compounds from cellular BitSA and degradation screens

38	Carl	Haslam	Artios Pharma	Developing and Embedding Compound Management within Artios
39	Alexander	Haworth	Metrion Biosciences	Using high-throughput automated patch clamp electrophysiology to identify novel TREK-1 modulators in an animal venom library
40	Andrew	Hayward	Genedata	Automatic Assignment of Biacore SPR and Octet BLI Kinetic Binding Curve Profiles with Artificial Intelligence
41	Sam	Hoare	Montana Molecular	Quantifying the kinetics of metabolic G-protein-coupled receptor signalling using high performance biosensors and a curve fitting platform
42	Benedikt	Hölbling	Mrc Lms/imperial Drug Discovery Hub	Introducing the Imperial-LMS Drug Discovery Hub
43	Zeki	Ilkan	Metrion Biosciences	Fluorescence-based drug repurposing screen of the potassium channel, KV3.1 with V434L mutation
44	Megan	Jones	ARUK UCL DDI	Development of a functional cell-based assay and cellular thermal shift for evaluation of drug target interactions with Phospholipase C-gamma 2, PLCγ2
45	Jiyun	Kim	Ministry of Food And Drug Safety	Current Efforts to Develop Analytical Tools for Mitigating Nitrosamine Impurities in Medicines
46	Linda	Kitching	Astrazeneca	Accelerating Drug Discovery with NanoSAR PROTAC Libraries, Innovative Platforms and Advanced Assay Development
47	Veronika	Kozlová	Solgate GmbH	Solgate: Discovering The Next SLC Drug With A Dedicated Platform Approach
48	Dhaluni	Kudagamage	LifeArc	Assessing live-cell imaging probes to track stress granule dynamics within in vitro models relevant to neurodegeneration
49	Pierre	Le Ber	Minos Biosciences	First-in-class discovery platform allowing one-to-one mapping of cellular phenotype and genotype
50	Charles	Leach	Ncardia	Development of robust iPSC platforms for accurate predictions of efficacy and toxicity of new treatment modalities that are early in the development pipeline
51	Freya	Leif	Bmg Labtech	Structure-guided monitoring of the human opioid receptor family using BRET assays
52	Dagmara	Lewandowska	Integra Biosciences Ag, Innovation And R&d Departement	Reliable and cost-effective library preparation with INTEGRA's MAGFLO NGS beads for Illumina MiSeq amplicon sequencing
53	Frank	Liu	Revvity	dCas9-SALL1-SDS3, a novel CRISPRi effector, can help uncover novel drug-gene and gene-gene interactions with higher confidence than traditional CRISPRi approaches
54	Blaise	Louis	Semarion	Streamlining Transient Transfection Assays: Freezing Adherent Cells with SemaCyte® Microcarriers
55	Maryna	Löwe	Cube Biotech	Next Generation Polymers for the Characterization of Membrane Proteins in Near-Native Conditions

56	Katharina	Lutz	Hoffmann-La Roche AG	Diligent Design and Screening of BrS-ASO conjugates to enable peripheral drug delivery to the brain
57	Ben	Mackison	Cancer Research Horizons	A Curiously High Interference Rate Drives the Need for Greater Understanding
58	Philippa	Malko	Sygnature Discovery	Fast Isolation and Characterisation of Rat Oligodendrocyte Precursor Cells for Differentiation and Proliferation Studies
59	Tika	Malla	University of Oxford	Optimisation and application of a high throughput cell based assay to screen for molecular glues of SHIP1, a drug target in Alzheimer's disease.
60	Martin	Mangold	Bmg Labtech	Measuring protein ligand binding with an endogenous HiBiT CETSA test system
61	Masahiro	Matsumoto	Sony corporation	Microfluidic device for the high-throughput and selective encapsulation of single target cells
62	Teresa	Matthews	Apex Molecular	Psychoactive capabilities at Apex Molecular
63	Geneva	Mayuga	Sphere Fluidics Limited	Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery and Development Process
64	Joshua	McArthur	Charnwood Discovery	Speeding up PROTAC Development: A Direct-to-Biology Approach for Rapid Optimization of PROTACs, comparing HiBiT and transiently expressed NanoLuc ® Approaches
65	Lorena	MEJIA	Malvern Panalytical	KINETIC SCREENING USING GRATING COUPLED INTERFEROMETRY (GCI) – HIGHLY SENSITIVE BIOSENSOR-BASED ASSAYS ENABLE THE IDENTIFICATION OF WEAK FRAGMENT HITS ACROSS A DIVERSE SET OF CHALLENGING TARGETS.
66	Mariachiara	Micaelli	IRBM SPA	Development of biochemical and biophysical assays for the identification of peptides targeting the MLH1-MSH3 protein-protein interaction
67	Yannick	Nossin	Cell Signaling Technology	Fit-for-Purpose Validation of Cell Signaling Technology® Antibodies for Simple Western™ on the ProteinSimple Jess™.
68	Federico	Olivero	Metrion Biosciences	Scientifica PatchScope Pro: an integrated calcium-imaging and patch-clamp system suitable for selecting specific subsets of neurons for electrophysiology recordings
69	Marco	Ortiz	CN-bio	Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability
70	Jaime	Padros	Bioauxilium Research	High performance TR-FRET assays for the measurement of phosphorylated human STAT1, STAT3 and STAT6 in cell lysates using THUNDER TR-FRET
71	Aimee	Parsons	Merck Life Science	MILLIPLEX® PLEXpedition panel: a customizable multiplex immunoassay kit developed to simultaneously screen up to 115 targets including cytokines, chemokines, growth factors, matrix metalloproteinases, and biomarkers of bone health, metabolism, and cardiovascular disease
72	Rita	Pereira	Bioascent Discovery Limited	A FLIPR Assay Screen of a 5K Compound Library to Identify Potential Positive Allosteric Modulators of 5-HT2A Receptors
73	Thomas	Pesnot	Concept Life Sciences	Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI

74	Ana	Pires	Charles River Laboratories	HTT RNA Translation Modulation Assay Development
75	Dusan	Popov-Celeketic	Confocal.nl	Application of NL5+ by Confocal.nl in live cell confocal imaging
76	Omar	Qureshi	Celentyx Ltd	Human in vitro immuno-oncology models for the identification and characterisation of potential immuno-oncology therapeutics; differential enhancement of responses by cytokines and antibody-based therapeutics
77	Philip	Rawlins	Domainex	Fragment Screening of Adenosine A2a Receptor using Native Lipid Nanodiscs
78	Dillon	Rinauro	Domainex Ltd	Strategic approaches to unlocking binding kinetics in complex protein systems using grating-coupled interferometry (GCI)
79	Henry	Robinson	Selvita	Case study for ADC Drug Discovery with Selvita; trastuzumab ADCs in HER2 positive breast cancer
80	Kimberly	Rockley	Apconix	Benefits of early in vitro screening for seizure liability in problem solving and decision making
81	Siobhan	Ryan	Charles River Laboratories	Delivering Mechanism of Inhibition Studies to Characterise Mutant Selective Kinase Inhibitors
82	Sharon	Sanderson	Bio-rad	StarBright Yellow, 561 nm Excitable Dyes, Superior Alternative to PE and PE-tandems with Improved Stability and Better Spectral Properties
83	Maitrayee	Sardar Sinha	Cellectricon AB	High-content imaging and multiparametric analysis of a chimeric in vitro model for assessment of microglia-targeted therapies in neuroinflammatory CNS disorders.
84	Christine	Schwenk	InSphero AG	On the relevance of human liver microtissues for the detection of hepatoxic drugs early in the drug development process
85	Andy	Scott	Concept Life Sciences	Biophysical Characterisation of Therapeutic Monoclonal Antibodies – Stability and Forced Degradation Studies
86	Fitzwilliam	Seibertz	Nanion Technologies Gmbh	A Holistic Perspective: Investigating Electrophysiology and Contractility of atrial vs ventricular hiPSC-cardiomyocytes
87	Hannah	Semple	AstraZeneca	MRC funded Small Molecule High Throughput Screening: Leveraging AstraZeneca Facilities and Compound Library
88	Kundan	Sharma	Nuclera	Cell Free Expression of E3 Ubiquitin Ligases to accelerate Target Protein Degradation Studies
89	Jonathan	Sheard	UPM Biomedicals	Advanced 3D Cell Culture Models Using GrowDex Hydrogels for Cancer Research and High-Throughput Screening Applications
90	Antony	Sheehan	TGR BioSciences (an Abcam Company)	AlphaLISA® SureFire® Ultra™ technology as a unique platform to demonstrate TREM2/DAP12 signalling cascade activation in the neuroinflammatory disease space.
91	Sophie	Snow	Lifearc	Development of a novel flow cytometry-based epitope binning assay.

92	Anna	Stikane	Latvian Institute Of Organic Synthesis	Quantitative analysis of cardiolipin and competitive binding assay to fast forward breakthroughs in mitochondrial research
93	Simon	Stockwell	o2h Discovery	High-content analysis of DNA damage markers in multiplexed cell lines using the SemaCyte® microcarrier platform
94	Leigh	Stoddart	Excellerate Bioscience	Integrating signaling kinetics into GPCR compound profiling.
95	Alan	Strunga	Masaryk University	Staphylokinase: Revitalizing an Old Idea with Modern Approaches
96	Anna	Suchy	Selvita	High Content Screening as a Window to Understanding and Modulating Ageing Pathologies for Drug Discovery
97	David	Sykes	Z7 Biotech Ltd	Precision pharmacology tools reveal ligand-receptor transducer bias
98	James	Taylor	Samsara Therapeutics	Identifying new hits from a high-throughput phenotypic screen for autophagy inducers via machine learning image analysis
99	Giusy	Tornillo	Molecular Devices	Human organoid lines for modelling the intestinal epithelial barrier in vitro
100	Mara	Tornincasa	Axxam	Development of a High-Throughput Platform for the Identification of C3 and C3b Inhibitors in the Complement Cascade
101	Megan	Townsend	Samsara Therapeutics	A high-content imaging assay for measuring the re-localization of the CMT1a protein PMP22 by autophagy inducers
102	Owen	Underwood	Z7 Biotech Ltd	ModuMelt™: Allosteric Modulator hit confirmation and characterisation
103	Dmitry B	Veprintsev	Z7 Biotech Ltd	SolThermoBRET(TM): Assessing ligand-induced stabilisation of soluble proteins
104	Robert	Vries	Hub Organoids	Reconstructing tumour microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies
105	Paul	Vulto	Mimetas	An automated and multiplexed liver fibrosis screening assay on a microfluidic liver model that replicates the cellular composition and organization of the hepatic lobule
106	Daniel	Weekes	Semarion	Transforming Image-Based Assays: Optical Barcoding and High-Order Multiplexing with the SemaCyte® Multiplex Platform.
107	Alex	Wilkinson	OMass Therapeutics	GSDMD nanobodies inhibit pore formation but not GSDMD cleavage and can be used in structural biology studies to determine the GSDMD-caspase-1 complex
108	Zoe	Williams	University Of Birmingham	Multiplexing the Colour Competition Assay with a mechanistic output to enrich the data output
109	Clare	Wilson	Sygnature Discovery	Discovery of Novel Ligase Ligands Using Affinity Selection Mass Spectrometry (ASMS)

110	Andrew	Wood	Vernalis	Discovery of novel Trim21 and ML-IAP ligands useful for the targeted degradation of neo-substrates
111	James	Wood	Excellerate Bioscience Ltd	Kinetic phenotyping of monocyte-to-macrophage differentiation using quantitative phase imaging ptychography
112	Hina	Zamir	University of Leicester	Comprehensive analysis of PTK7-ADC responses in Breast Cancer Patient-Derived Explants: Investigating Multimodal Data for Personalized Medicine
113	Ali	Abdalla	Sudanese Academy of young scientists	GUM ARABIC. A PROMISING AGENT FOR PREVENTING CISPLATIN. CHEMOTHERAPY-INDUCED NEPHROTOXICITY
114	Blessing	Airhihen	Nottingham Trent University	Could Polyphenolic Compounds and Vitamin combinations delay Alzheimer disease progression?
115	Robert	Atkinson	Laverock Therapeutics	Gene Editing induced Gene Silencing (GEiGS®) - A new technology to transform advanced therapies by programmable gene silencing
116	Tia	ATTIA	University of Sunderland	Application of the microfluidic system for preparation of doxorubicin liposomes co-loaded with natural antioxidants for anti-tumour synergism and formulation stabilisation.
117	Lauren	Brown	University Of Nottingham	An assessment of mu-opioid receptor reserve on opioid-related behaviours using a pseudo-irreversible antagonist
118	Denice	Chan	Cancer Research Horizons	Perspectives on the Discovery of ADC Therapeutics for Novel Targets in Oncology
119	Elizabeth	Cosgrove	The Institute of Cancer Research	Synthetic oligonucleotides as RNA helicase inhibitors: An oligomimetic approach
120	Eimear	Flanagan	Sygnature Discovery	Radiotherapy sensitises preclinical models to DNA damage response agents
121	Sophie	Harding	Anglia Ruskin University	Phosphodiesterase inhibition prevents myofibroblast transformation in Peyronie's disease
122	Helen	Harrison	Storm Therapeutics Limited	Working towards pandemic preparedness: Inhibiting viral 5' RNA cap methylation with potent, selective, broad-spectrum small molecules
123	Xenia	Kodji	Charles River Laboratories	A high content, drug repurposing approach to identify novel treatments for PEX10-mediated Peroxisome Biogenesis Disorder (PBD)
124	Toskë	Kryeziu	University Of Prishtina, Faculty Of Medicine	Nanotechnological Approaches in Cancer Therapy: Essential oil Nanodelivery Systems
125	Tushar	Kushwaha	All India Institute Of Medical Sciences, New Delhi	Engineering antibody-like scaffolds against the extracellular domain of Epidermal Growth Factor Receptor for the treatment of lung cancer
126	Alice	Lapthorn	Anglia Ruskin University	Phenotypic drug discovery for fibrosis – the answer to a decades old problem?
127	Sophie	Mayle	Bio-rad Abd Serotec	Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform
128	Jack	Morton	university of nottingham	Arenavirus-based infection as a targeted non-lytic anti-cancer virotherapy

129	Sylvie	Moureau	Immunocore	Development of T cell receptor (TCR) x CD3 bispecifics to provide a functional cure for HIV
130	James	Murphy	Eleven Theraputics	DELiveri®: A high-throughput, hypothesis-free screening platform for identifying novel delivery molecules for RNA therapeutics.
131	Larissa	Ouro-gnao	GSK	Comparison of Sequence Diversification Methods for Accelerated Antibody Optimisation
132	Alexandre	Peter	Genedata	Integrated Analysis of Assay Data Drive Early Developability Assessment of Large Sets of Antibody Candidates
133	Alannah	Shaw	University of Nottingham	Maxi Potassium (BK) Channels and their Role in Membrane Stretch in Glioblastoma Multiforme
134	Kartika	Shetty	Domainex Ltd	The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate
135	Harvinder	Virk	University Of Leicester	Robust antibodies to accelerate basic science and drug development: the OGA community and YCharOS
136	Gillian	Watt	Pharmaron Uk	Translational insights support the discovery of selective PARP1 inhibitors with low human dose prediction
137	Joanne	Wayne	Pharmaron	Linking activity across multiple in vitro assays is key for molecule understanding and progression
138	Hannah	Mizen	Five Alarm Bio	Effects of Novel Small Molecule Compounds on Longevity, Senescence and Wound Healing
139	Krzysztof	Potempa	BRAINCURES	Biological Intelligence Approach to De-Risked and Faster Drug Development for Synaptic Plasticity-Linked Diseases
140	Amani	Rageh	University Of Wolverhampton	Bioinformatics analyses of interactions between skeletal myoblast secretome proteins and proteins associated with osteoarthritis and rheumatoid arthritis
141	Daniel	Rock	MSD	A progerin-driven model of accelerated ageing in human neural stem cells uncovers novel geroneuroprotectors
142	Chris	Ward	StrataStem Ltd	The StrataStem Manchester AD Cohort: Sporadic Alzheimer's Disease is Associated with Ciliopathic SNPs
143	Kirsty	Winn	Selvita	Supporting Healthy Ageing Research & Therapeutic Strategies for Senescence
144	Qilong	Wu	University Of Oxford	Target enablement for protein kinase STK32B
145	Benjamin	Bader	Nuvisan	Methods for Characterization and Derisking of Small Molecule Hits and Leads – Learnings from RAS-SOS1 and Hippo pathway Screens
146	Xiangrong	Chen	University Of Oxford	Discovery of novel human KLHL40 chemical and substrate binders
147	Joel	Cresser-Brown	Bio-Techne	Generation Cereblon Ligands: Design, Synthesis, and

				Extensive Characterization of BRD4 Degraders for In Vitro and In Vivo Exploration
148	Neha	Dhimole	Nanotemper Technologies	Biophysical and Biochemical Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
149	Fredrik	Edfeldt	Astrazeneca	Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin
150	Enhui (Grace)	Jin	Universtity Of Manchester	Mechanistic Study of Binary Weapon B10 Co-treat with Gemcitabine in Cancer: Implications for Chemo-Therapeutic Enhancement in Cancer Cells
151	Merve	Koch	Novartis	Small molecule induced STING degradation facilitated by the HECT ligase HERC4
152	Philip	MacFaul	Sygnature Discovery	Dedicated DMPK for Degraders - a flexible approach for flexible molecules
153	Sibusiso	Malindisa	University Of South Africa	Preclinical Study of EzecurminTM for Cancer Therapy
154	Amanda	Miles	ChemPartner	BREAKING NEW GROUND - NOVEL PRECLINICAL MODELS FOR PROTAC EVALUATION
155	Urvashi	Patel	University Of Leicester	Structural and Chemical Biology Investigations into Class I Histone Deacetylase Ubiquitination and Proteasome Mediated Degradation
156	Christopher	Wellaway	Pharmaron	Protein Degrader Discovery Platform at Pharmaron
157	Martha	Asare	West African Center for Cell Biology and	Riboflavin Re-sensitization of Fluoroquinolones and Carbapenems Against Critical Priority Pathogens
158	Jenna	Bradley	Astrazeneca	Sustainability considerations for functional genomic screening
159	Hannah	Cole	Durham University	Green Chemistry to the Rescue: Utilising Micelle Methodology to Access Small Molecules in Antiparasitic Drug Discovery.
160	Ian	Holland	University Of Edinburgh	RIFLE: A new technology for biofabricating layered human tissue for drug discovery research
161	Sarah	Marsh	Atelerix Ltd	Transforming the Storage and Shipment of In Vitro Cell Models & Tissues using Atelerix's Hydrogel Technology
162	Amy	Sanders	Astrazeneca	Pioneering the Push to Reduce Cell Culture's Reliance on Foetal Bovine Serum
163	Sergiy	Tokar	Metrion Biosciences	GLP hERG Assay Validation following ICH E14/S7B 2022. Q&A best practice guidelines
164			ELRIG	

165			ELRIG	
166			ELRIG	
167	Paul	Gunning	University Of York	Advanced Microscopy, Spectroscopy, Flow Cytometry, Genomics, Proteomics and Protein Production services at The University of York
168	Shazia	Hyatt	Virtual Scientia	Lab Without Limits - Revolutionising STEM Training through Immersive Virtual Laboratory Training with AI-Powered Digital Twins
169	Bec	Johnston	Srg Talent	Discovery By SRG: Engaging Talent to Support your Journey
170	Anja	Mathiesen	Nicoya Lifesciences	Characterization of Therapeutic Antibodies using Digital SPR
171	Gehad	Mohamed	Keele University	Targeting BCKDK: Exploring its Role in Cancer Metabolism and Drug Resistance
172	Chitra	Seewooruthun	Leicester Drug Discovery And Diagnostics	Leicester Drug Discovery and Diagnostics (LD3): Accelerating translational research and drug discovery.
173	Charlotte	Bayley	The Institute Of Cancer Research	Novel Fluorescent Probes for Imaging Reactive Metabolites
174	David	Bushiri Pwesombo	Leibniz-Forschungsinstitut für Molekulare	Semi-supervised Contrastive Learning for Bioactivity Prediction using Cell Painting Image Data
175	Diya Rajasekhar	Chinta	Manipal University College Malaysia	Pharmacoinformatics exploration of a traditional antipsoriatic oil for its potential against proinflammatory cytokine TNF-α
176	David	Egan	Core Life Analytics	Deep Dive into the JUMP-CP Dataset: Leveraging the Power of a Cloud-based Analytical Platform with an AI Search Engine for Rapidly Unlocking Novel Biological Insights
177	Robert	Francis	Abzena	Real-Time Live Cell Imaging in Successful Antibody-Drug Conjugate Development
178	Alberto	García Nieto	A4cell	SPAchip® image analysis: from a versatile intracellular monitoring of physiological processes to meaningful data
179	Magdalena	Grzeszczuk	Healx	Generation of Phenomic profiles of the clinical candidate HLX-1502 to interrogate the biological and pharmacological landscape of Neurofibromatosis type 1.
180	Shushant	Jain	Ncardia	Leveraging iPSC-Derived Cardiomyocytes, Sensory Neurons, and Astrocytes with Cell Painting for Advanced Phenotypic Drug Discovery
181	Emma	Kerklingh	Lumicks	Advancing Drug Discovery with High-Resolution Single-Molecule Dynamics: Unlocking New Insights into Molecular Interactions
182	Felix	Lavoie-Perusse	Saguaro Biosciences	Live Cell Painting: an Exploration of Time-Dependent Phenotypic Changes for enhanced drug discovery
183	Li-Li	Li	Turku Bioscience Centre, University of Turku	Development of phenotypic assays for high-throughput screening of small molecules targeting diseases caused by SYNGAP1 mutations

184	Radoslaw	Lukoszek	National Phenotypic Screening Centre	Sperm Cell Painting: A Mechanism Driven Approach for Drug Discovery in Human Spermatozoa
185	Magdalena	Otrocka	Ardigen	Deciphering Cellular Mechanisms through Phenotype: CRISPR-Induced Perturbations Analyzed Using Cell Painting and Machine Learning.
186	Christopher	Schmied	EU-OPENSCREEN ERIC	Morphological profiling datasets based on EU-OPENSCREEN compound libraries.
187	Laura	Sesma Sanz	National Phenotypic Screening Centre -	National Phenotypic Screening Centre at the University of Dundee, Scotland (UK): High-Content Imaging for all
188	David	Sorrell	Revvity	Illuminating the Path to Innovation: Revvity's High Content Screening Services
189	Victor	Wong	Core Life Analytics	Cell Painting in Pictures and Numbers: A Robust Image and Data Analytics Workflow for Accelerating Drug Discovery
190	Lucy	Adam	University Of Nottingham	Differential Regulation and Signalling Mechanisms of Proton-Sensing GPCRs via the GRK/Arrestin Pathway: Implications for Acidosis-Driven Pathologies
191	Mehwish	Akram	Sygnature Discovery	Electrophysiological characterisation of functional and phamacological effects of β subunit expression on BK channel activity
192	Nermeen	Ali	Ulster University School of Pharmacy	New Series of Fluoroquinolone Analogues as Potential Anticancer Agents: Design, Synthesis, In Vitro Biological Evaluation, and Topoisomerase II Inhibition
193	Theebaa	Anasamy	Manipal University College Malaysia	Unveiling the Upstream Anticancer Mechanisms of Tribenzyltin Carboxylate Complexs: DNA Minor Groove Interaction and Multifaceted Enzyme Inhibition
194	Ashley	Barnes	Axol Bioscience	Development of iPSC-derived 3D human brain micro-tissues for drug discovery applications
195	Sonika	Bhatnagar	Netaji Subhas University Of Technology	Machine learning for selection of novel therapeutic targets of infectious diseases using host pathogen interaction networks
196	Rachel	Bleach	Inventia Life Science	High throughput characterization of advanced 3D liver models for in vitro hepatotoxicity studies
197	Philip	Bousfield	AstraZeneca	Modelling renal tubulointerstitial fibrosis: kidney fibroblast (HKF) characterisation followed by development of HKF/proximal tubule epithelial cell (PTEC) co-culture
198	Ellie	Bravington	Msd	Optimising 3D bioprinted models of iPSC-derived glutamatergic neurons for use in oxidative stress and mitochondrial dysfunction assays.
199	Richard	Broadhead	Quantum-si	Beyond the Genome: Unraveling Protein Variability with Quantum-Si's. Next-Generation Protein Sequencing™ Technology
200	Tom	Brown	Bit.bio	ioAstrocytes advance the development of reliable co-culture systems for CNS-related drug discovery pipelines
201	Tilmann	Buerckstuemmer	Myllia Biotechnology	A genome-wide CROP-Seq screen reveals mediators of T cell signaling

202	Michael	Burnett	Sygnature Discovery	Would rats like a smoke break? Validating the rat intravenous self-administration model for efficacy testing novel treatments for nicotine addiction.
203	Ann	Byrne	Bit.bio	Harnessing CRISPR-Ready ioGlutamatergic Neurons and ioMicroglia as functional genomics tools for drug discovery
204	Albert	Carter	Sygnature Discovery	Determination of the profile of a range of psychedelics for 5-HT1A, 5-HT2A and 5-HT2C receptors in rodent brain tissue
205	Emily	Cash	University Of Nottingham	Affinity and selectivity of caffeine at the 4 human adenosine receptors: potential impact for Bronchopulmonary Dysplasia.
206	Katherine	Czysz	FUJIFILM Corporation / Global CRO - Life	Ferroptosis-dependent neuronal damage induced by oxidative stress and TDP-43 aggregation formation in iPSC-motor neurons as ALS models
207	Annabelle	Dale	Axol Bioscience	Characterization of striatal neurons derived from >140 CAG iPSCs for Huntington's Disease modeling
208	Naomi	Den Breems	Mimetas	Influencing drug responses through in vitro tumor microenvironment characteristics
209	Elaine	Duncan	University Of Glasgow	Developing a 3D in vitro adipocyte model to investigate metabolite-sensing GPCR function
210	Aruba	Farooq	University Of Nottingham	Regulation of macrophage polarisation in the acidic pancreatic tumour microenvironment.
211	Erzsébet	Fichó	Cytocast Hungary	Cytocast Digital Twin Patient™ – Safer and smarter drug development
212	Jasmine	Forster	University Of Bristol	Development of Super-Resolution Microscopy Techniques for use in Mechanistic Studies
213	Millie	Fox	Astrazeneca	Semi-automated multiplexed arrayed CRISPR screening workflow for target discovery
214	Javier	Frias Aldeguer	Hub Organoids	3D In-Vitro Fibroblast-Patient Derived Organoid Co-Culture: A High-Throughput Platform for IBD Drug Development
215	Celia	Garcia	BMG Labtech	Extracellular ATP measurement in real time using living cells
216	Ilaria	Giovannelli	Phoremost	Systematic identification of novel Targeted Protein Degradation mechanisms using SITESEEKER® technology
217	Sneha	Girish Kumar	Manipal Institute Of Regenerative Medicine (mirm),	Protein kinase B inhibition as a target in Mycobacterium tuberculosis drug discovery
218	Ivan	Gladwyn-Ng	Taconic Biosciences	Evaluation of checkpoint inhibitor efficacy and/or engraftment in a humanized immune system mouse with and without transgenic human cytokine expression in a model lacking murine Fc gamma receptors.
219	Celine	Gomez	Definigen	iPSC-derived hepatocytes as a novel platform for modelling Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in vitro.
220	Alexander	Henrici	Technical University Of Munich	High Throughput Screening for Assessing Host-Virus Interactions and Identifying Potential Antiviral Compounds.

221	Louisa	Johnson	UCL	Using an astrocyte-focused in vitro platform to validate astrocytic cAMP signalling as a potential therapeutic target for Alzheimer's disease
222	Isobel	Jones	Sygnature Discovery	Measurement of the ability of three compounds including (±)MDMA to stimulate uptake and release of [3H]5-HT in rat frontal cortical synaptosomes
223	Christian	Kortleven	Fujifilm Cellular Dynamics	Targeted Applications for Investigating Pain and CIPN using iPSC-derived Sensory Neurons
224	Ulrike	Kuenzel	Astrazeneca	The AZ-MRC-MTI Functional Genomics Screening Laboratory (FGSL)
225	Michela	Leoni	Sanquin	CHARACTERIZATION OF THE INTERACTION OF BLOOD COAGULATION FACTOR VIII AND THE LIVER. SINUSOIDAL ENDOTHELIAL CELL RECEPTOR STABILIN-2
226	Rosa	Loffredo	Cellected Ltd	SEED & GO: An Improved Cryopreservation Method for Enhanced iPSC Reproducibility
227	Daniela	Lopes	Axion Biosystems	Optimization of a multiplexed, cell-based assay for characterization of cortical networks and their responses to neuroactive compounds
228	Susanna	Lovell	FOx Biosystems	Specific Extracellular Vesicle detection and isolation in complex samples
229	Dario	Magnani	Charles River Discovery	Development of an iPSC-derived human cortical neuronal network using multi-electrode arrays as a phenotypic model of chemically-induced seizures
230	Rosa Maria	Mella	Innoprot S.l.	NOMAD® Genetically encoded biosensors for multiplexing Histamine H1 receptor
231	Georgie	Middleton	UEA	G-quadruplexes: novel antifungal targets
232	Lambert	Montava Garriga	Astrazeneca	Powering up 3D patient-derived organoids: an integrated, multidisciplinary CRISPR organoid platform for target and drug discovery in oncology
233	Dylan	Mooijman	Single Cell Discoveries	Transcriptomic phenotyping of large scale drug perturbation experiments
234	Diana	Moreira Leite	Sygnature Discovery	Exploring lysosomal function in fibroblasts from Alzheimer’s and Parkinson’s disease patients: a platform for drug discovery
235	Otto	Morris	Exscientia	DepExML: An explainable machine learning pipeline for context-aware biomarker discovery
236	Daniel	Mota	Charles River Laboratories	Method Development of DRIP-qPCR for detection of R-Loops in Huntington’s Disease cell models
237	Christoph	Neumayr	Myllia Biotechnology	Design of highly efficient sgRNA libraries through comprehensive feature analysis
238	Joshua	Pearson	Crown Bioscience	The use of ultrasound guided injection to refine orthotopic implantation of in vivo hepatic and pancreatic tumour models
239	Maja	Petkovic	Amsbio	A Simple & Robust Cell-based Assay for Evaluating GLP-1R, GIPR, and GCGR Agonists

240	Dillon	Popat	OMass Therapeutics	Native Mass Spectrometry identifies C-Terminal Palmitoylation of MC2R which facilitates interaction with effector proteins, MRAP and Beta-Arrestin 1
241	Jonathan	Popplewell	Carterra	Deep characterization of binding kinetics for 210 kinase inhibitors against 80+ kinases
242	Valentina	Quarantotti	AstraZeneca	Identification and validation of novel radiosensitisers and their mechanism of action in lung cancer by genome-wide pooled and arrayed CRISPR screening
243	Shashank	Rai	MRC Laboratory Of Molecular Biology	Activation of the Integrated Stress Response: A new therapeutic strategy for diabetes
244	Helena	Raine	Axol Bioscience	Building a functionally relevant in-vitro model of Alzheimer's Disease with patient-derived iPSCs
245	Teresa	Raposo	Revvity	Tiled pooled screening with the Pin-point ™ base editing platform enables mutational scanning and high-resolution dissection of drug resistance mechanisms
246	Dan	Redfern	BIOGNOSYS AG	Quantitative profiling of HLA class I and class II antigens and neoantigens in tissue biopsy and PBMC samples using an optimized mass spectrometry-based workflow
247	Eva	Rico Vidal	BenevolentAI	Use of the Benevolent Platform™ to identify and accelerate the discovery of novel anti-fibrotic targets for the treatment of MASH
248	Naveed	Saleem	University College London	Liposomal antibiotics enhance bacterial killing and ameliorate systemic inflammation
249	Ellen	Sandom	Fujifilm Cellular Dynamics	Development of Cytokine Release Assays for Human iPSC-Derived Microglia
250	Nadia	Sarker	Wuxi Apptec Uk Ltd	Covalent fragment-based drug discovery (FBDD) workflow demonstrated on Bruton's Tyrosine Kinase
251	Henrik	Schmidt	Myllia	Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing
252	Aqeel	Shamsul	Frontier Space	Can space research improve drug discovery & development?
253	Nandana	Shankar	Functional Genomics Centre (CRH-AZ)	The Functional Genomics Centre -Enabling access to cutting-edge CRISPR technologies
254	Frank	Smith	Aliri Bioanalysis	Uncovering Novel Therapeutic Targets in Immune Checkpoint Inhibitor Resistance Using Spatial Proteomics in Metastatic Tumor Microenvironments
255	Liliana	Som	University Of Oxford	Characterisation of the smooth muscle cell phenotypic modulation: mechanisms and targets in vascular disease
256	Zofia	Świątczak	Editco Bio	Custom Human Primary T-Cells Pools Ready For Your Downstream Assays - Rapid And Efficient CRISPR-KO
257	Hannah	Taylor	University Of Leeds	The role of the Beta-secretase 1 (BACE1) enzyme in vascular dysfunction associated with metabolic disease and dementia
258	Amanda	Turner	bit.bio	A TOOLBOX OF HUMAN IPSC-DERIVED MICROGLIA IN DIFFERENT GENETIC BACKGROUNDS AND DISEASE MODELS FOR NEURODEGENERATION DRUG DISCOVERY

259	Aimee	Vaughan	University Of Leicester	Intrinsic expression of the cytokine receptor STX3 predicts response to α-PD-1 immune checkpoint inhibition in Non-Small Cell Lung Cancer
260	Daniel	Vaughan	Inventia Life Sciences	Tunable 3D cell models recapitulating the tumour microenvironment for in vitro immuno-oncology assays
261	Manu	Verma	Novo Nordisk Research Centre Oxford	Human Adipocyte Energy Expenditure and Diabetes Risk: A Genome-Wide Regulatory Perspective
262	Thomas	Waldmann	Crelux - A Wuxi AppTec Company	Advancing Drug Discovery for Membrane Proteins: Integrated Platform for Targeting GPCRs, Ion Channels, and Transporters
263	Nicolas	Walker	Enhanc3d Genomic	3D Genomics Illuminates The Dark Genome
264	Emily	Wallace	Cancer Research Horizons	Multiple Screening Approaches in Drug Discovery
265	Ashia	Wheeler-Crawford	University of Nottingham	The Role of bromodomain and extra terminal (BET) proteins in angiogenesis in triple negative breast cancer.
266	Amy	Williams	University Of Nottingham	Age-associated grey and white matter volume changes in paediatric temporal lobe epilepsy patients and healthy controls
267	Arianit	Zajmi	University of Prishtina "Hasan Prishtina",	Why Indomethacin is Unique Among NSAIDs: A Review of Its Role in Headache Treatment and Potential for Nanotechnology-Based Delivery Systems
268	Pingping	Zheng	Hull York Medical School	Potential antioxidant and renoprotective effects of novel H2S-releasing compounds: Pilot study on human podocytes in vitro
269	Nicholas	Akosa	MFX	Screening of Treg culture conditions using a novel scalable bioreactor
270	Scott	Brouilette		A Drop of Insight: Single Cell Functional Profiling for Immunotherapy
271	Emma	Burman	UCL	EV-olution of Extracellular Vesicle Isolation
272	Andrew	Chai	University Of Edinburgh	Depletion of COL1A1-positive non-neural cells for improved cortical differentiation of human pluripotent stem cells
273	Scott	Cribbes	Revvity -	Developing image based T cell assays to effectively monitor apoptosis and CAR expression
274	THOMAS	EDMONDS	TEBUBIO	RNA Production & tools Help R&D RNA-Based Vaccine
275	Claudia	Fernandes	Isogenica	Small is beautiful - VHHs enable multi-specific targeting for tandem-CAR therapies
276	Harrison	Garner	Cytena Gmbh	An optimized and validated workflow for developing stable producer cell lines with >99.99% assurance of clonality and high clone recovery
277	Maria	Kalli	MFX Ltd	Improved transduction and expansion of CAR-T generation in novel scalable bioreactors

278	Malte	Pinckert	VectorBuilder	miniVec: improving safety and performance for ATMP developers using next-generation vectors
279	Eve	Stalker	University Of Cambridge	The epigenome as a novel player in CRISPR safety.
280	Yoki	Wang	University College London	In silico Investigations of the role of Non-Receptor Tyrosine Kinases in Enhancing Production of Extracellular Vesicles
281	Zhong	Yu	Axion Biosystems	Evaluation of plate-to-plate reliability in a label-free cytotoxicity assay for dose response analysis
282	Chris	Becker	Aurora Microplates	Zeon original coating technology COP microplates for cell imaging
283	Marc	Botcherby	Shelford Scientific	A Chip-based Immunogenicity Risk Assessment Tool for Therapeutic Protein Products
284	Alistair	Boyd	University Of Oxford	Structure-based design of selective, high affinity macrocyclic ligands targeting the CBP/p300 bromodomains
285	Rebekah	Clarke	Swansea University	Developing Small-molecule Inhibitors of GATA2: a novel approach to target leukaemic blasts and stem cells in therapy-resistant acute myeloid leukaemia
286	Jessica	Coley	Compare - University Of Nottingham	Development of a ligand directed fluorescent label for adenosine A3 receptor with retained orthosteric binding site accessibility.
287	Holly	Cooper	Artios	Mechanistic and structural characterization of PolQ targeted covalent inhibitors
288	Cherise	Dixon	Birmingham City University	Investigating the effects of Artesunate and Resveratrol individually and in combination on Ishikawa endometrial cancer cells
289	George	Farmer	Univeristy Of Nottingham	NOVEL FLUORESCENT ANTAGONISTS FOR THE NOCICEPTIN OPIOID RECEPTOR (NOR) TO FACILITATE THE DEVELOPMENT OF IMPROVED OPIOID PAINKILLERS
290	Sophia	Hamza	Indiana University Bloomington	Next-Generation Hit Discovery: Advanced hybrid AI/ML-Shape Ligand screening method
291	Georgia	Howick	University Of Sunderland	Probing the substrate specificity of γ-glutamyl transpeptidase (GGT1) for exploitation in drug discovery and diagnostics.
292	Mio	Hu	University Of Southampton	UK-China project to tackle antimicrobial resistance. Chinese Herbal medicine to aid AnTibiotic use reduction in exacerbation of Chronic Obstructive Pulmonary Disease
293	Saidu	Kamara	University Of Oxford	Inducing immunogenic cell death via organelle-specific targeting of photosensitizers
294	Shakeel	Khan	The Hong Kong Polytechnic University	Polypharmacology-Based Innovation: ZAK-I-57 as a Potent Multi-Target Therapy for Hepatocellular Carcinoma
295	Alex	Mcclarron	Institute Of Cancer Research	Structure-based drug discovery towards non-peptidomimetic inhibitors of ERAP2
296	Giuseppe	Palazzo	Swansea University	Targeting the NS1-2 protein: computer-aided discovery of novel therapeutics for Norovirus infection.

297	Niamh	Parkinson	University Of Birmingham	Developing stabilisers for the interaction between 14-3-3 and hDM2 or hDMX
298	Benjamin	Rahemtulla	Pharmaron UK Ltd	Novel Syntheses of Pyrroles and Enantioenriched Morpholines with Improved Synthetic Efficiency
299	Anusha	Rajkumar	M S Ramaiah College Of Arts, Science And	Antimicrobial and Dihydropteroate synthase inhibition effects of substituted thiazole imidazolidine derivatives
300	Jiri	Ruzicka	School of Pharmacy, Cardiff University	Targeting the interaction between the viral N protein and the host MASP2 protease to discover novel broad-spectrum therapeutics for coronavirus infections
301	Luigia	Salerno	Ucl (aruk Ddi)	A Small Molecule Drug Discovery Approach to Inhibit. Notum and Activate Wnt Signalling in the Brain
302	Teresa	Sardon	Fundacion Medina	Chemical diversity in Natural Product Libraries: a way to expand Discovery Programs
303	Elliott	Smyth	LifeArc	De-Risking Non-Structural Protein 14 (NSP14) as a Novel Target for the Treatment of Human Coronaviruses
304	Rohini	Srivastava	UCL School Of Pharmacy	Therapeutic Targeting of KEAP1-NRF2 Axis to Tackle Cancer Drug Resistance
305	Katie	Thomas	The Institute Of Cancer Research	Exploring the SAR of cyclin K degraders
306	Laharika	Vusa	M S Ramaiah College Of Arts, Science And	Fungal kinase inhibition and antifungal effects of novel methyl thiazolquinolines
307	Daniel	Arismendi	Ridgeview Instruments AB	Complex Real-Time Interaction Analysis in Drug Discovery and Development: Tools for Biological Insights
308	Graham	Ball	Intellomx Ltd	AI-based causal modelling of Sjogren disease using Swarm-based Neural Networks to inform therapeutic target identification.
309	Tobias	Brode	Liquimetrix Gmbh	Contactless Volume Verification in Microtiter Plates: Precision Monitoring Across Liquid Types and Plate Formats
310	ZEXIN	CHEN	Guangdong Research Center of Organoid	Combination of IT & BT——A Potential Paradigm for Drug Development Based on Organoids and Artificial Intelligence
311	James	Dale	Pharmenable Therapeutics Limited	INTRODUCING CHEMSEEK: PHARMENABLE'S AI-ENABLED SMALL MOLECULE DRUG DISCOVERY PLATFORM
312	Adam	Darby	Astrazeneca	Enabling Functional Genomic Screens through Data and Laboratory Automation
313	rebecca	fairclough	Astrazeneca	Multimodal Cell Profiling: A new paradigm for Hit-ID and SAR?
314	Suzanne	Fuld	Nuclera	DNA to assay-ready proteins in 48 hours. Rapid protein expression and purification on the eProtein Discovery™ system and binding confirmation on Biacore™ SPR System
315	Becky	Guza	Computype	Modern labware identification options that maximize laboratory automation and enable AI/ML

316	Daniel	Hansen	Carl ZEISS Ltd.	From Image to Results | Novel Approaches to Measure Receptor-Mediated Endocytosis of Herceptin
317	Kate	Harper	Revvity	Nuclei Segmentation on Brightfield Images using a pre-trained Artificial Intelligence (AI) Model
318	Delyan	Ivanov	Astrazeneca	FRET prioritisation score to choose high-quality hit equity in High Throughput Screening
319	Max	Jakobs	Deepmirror	Designing 10x less toxic antimalarials in 60 minutes
320	Melanie	Jamard	WuXi AppTec UK, Ltd	A Comprehensive Structural Biology Platform for Structure-Based Drug Discovery
321	Sudeep	Joshi	The Francis Crick Institute	VISIBLE: A robotic process automation system for biomanufacturing animal-free in-vitro 3D tissue and organoid models for drug screening
322	Mateusz	Kaczynski	EAC / Arachne.ai	Unlocking the Opportunity Space for Permeability Enhancement Technology with an In-Silico Platform
323	Christopher	King	Fusion Antibodies plc	AI Assisted De-Novo Design and Discovery (Aim-Lab)
324	Scott	McDonald	Optibrium	Addressing Common Metabolism Problems in Drug Discovery with in Silico Methods
325	Aditi	Pradhan	Astrazeneca	In-house built AI/ML-powered tool, PhenoSpace, enables robust high-content imaging assay development
326	Ahmet	Şahin	Bezmialem Vakif University	The Quest for Ligands Against Kinesin Motor Proteins Using CADD
327	Sara	Schmidt	Astrazeneca	Implementing Data and AI Tools into our Discovery Workflows
328	Barbie	Wang	Astrazeneca	Detection of cellular drug response through image-enabled cell sorting for downstream development of a machine learning aided indication discovery platform